Insulin detemir: A historical perspective on a modern basal insulin analogue.

Abstract

Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets.

• Authors: Luigi Meneghini, Andreas Liebl, Martin J Abrahamson
• Journal: Primary care diabetes (Prim Care Diabetes) Vol. 4 Suppl 1 Pg. S31-42 (Apr 2010) ISSN: 1878-0210 [Electronic] England
• PMID: 20394890 (Publication Type: Historical Article, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: 2010 Primary Care Diabetes Europe. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Hypoglycemic Agents
• Insulin
• Insulin, Long-Acting
• Insulin Detemir

Topics

• Diabetes Mellitus, Type 2 (drug therapy, history)
• History, 20th Century
• History, 21st Century
• Humans
• Hypoglycemic Agents (history, therapeutic use)
• Insulin (analogs & derivatives, history, therapeutic use)
• Insulin Detemir
• Insulin, Long-Acting